Mcp- Sf

Metoclopramide Hydrochloride Monohydrate, the active ingredient in Mcp- Sf, is a dopamine antagonist (antiemetic, gastro‑prokinetic) presented as an injectable for intramuscular and intravenous use. It treats nausea, vomiting and gastroparesis in adult patients.

GNH USA supplies Mcp- Sf as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metoclopramide acts on the dopaminergic pathways that trigger nausea and on gastrointestinal motility, making it useful for several related conditions.

Nausea: reduces the frequency and severity of nausea episodes. Vomiting: controls acute and chemotherapy‑induced vomiting. Gastroparesis: enhances gastric emptying and alleviates related symptoms.

Metoclopramide may cause a range of adverse reactions, which are grouped by frequency.

Common Side Effects: - Drowsiness: feeling unusually sleepy or fatigued. - Restlessness: inner sense of unease or agitation. - Diarrhea: loose, frequent stools.

Serious or Rare Side Effects: - Extrapyramidal reactions: involuntary muscle movements or rigidity. - Tardive dyskinesia: persistent, irreversible facial or limb movements. - Neuroleptic malignant syndrome: rare, life‑threatening reaction with fever and muscle rigidity.

Before using Metoclopramide, several safety considerations should be observed.

Assess renal function: adjust use in patients with impaired kidney function. Monitor for extrapyramidal symptoms: watch for involuntary movements during therapy. Use with caution in depression: may worsen depressive symptoms. Avoid in known hypersensitivity: discontinue if allergic reaction occurs. Limit duration to ≤12 days for nausea/vomiting: reduces risk of tardive dyskinesia. Store at room temperature: keep in original container, protect from moisture and light.

Metoclopramide can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Antipsychotics (e.g., haloperidol): antagonistic effect reduces therapeutic benefit. - MAO inhibitors: may precipitate hypertensive crisis. - CYP2D6 inhibitors: increase metoclopramide plasma concentrations.

Moderate Interactions (Monitor Closely): - Opioids: additive central nervous system depression. - Anticholinergics: may diminish pro‑kinetic activity of metoclopramide.